Table 1. Patient characteristics, diagnosis, treatment and outcomes.

Patient	Age	Sex	Main diagnosis	Treatment	Outcome
1	72	F	Native mitral valve endocarditis	Surgery with tissue mitral valve replacement. IP ABX and OP ceftriaxone 2 g BD for 15 days	Readmissions with unwell and raised CRP
2	97	M	Native valve infective endocarditis	IP ABX and 12 days of OP ceftriaxone 2 g OD	Readmission with pulmonary embolism
3	78	F	Native tricuspid endocarditis	IP ABX and 16 days of ceftriaxone 2 g BD	None
4	47	F	Pericarditis	IP ABX and 18 days of ceftriaxone 2 g OD and teicoplanin 80 mg	None
5	68	M	Late prosthetic aortic valve endocarditis	IP ABX and 12 days of ceftriaxone 2 g OD	None
6	36	M	Infected pericardial effusion	IP ABX and 36 days of ceftriaxone 2 g OD	None
7	66	M	Native aortic and pulmonary valve endocarditis	IP ABX and 20 days of ceftriaxone 2 g BD	None
8	52	M	Native aortic valve endocarditis	Revision of total hip replacement. IP ABX and 28 days of ceftriaxone 2 g BD	None
9	46	F	Early prosthetic valve endocarditis	IP ABX and 13 days of ceftriaxone 2 g BD	None
10	85	F	Late prosthetic aortic valve endocarditis	IP ABX and 14 days for daptomycin 350 mg and rifampicin	Readmission with elevated CK. Daptomycin switched to flucloxacillin 4 g/day
11	75	M	Late prosthetic aortic valve endocarditis	IP ABX and 29 days of OP ceftriaxone 2 g OD	None
12	69	F	Native mitral valve endocarditis	IP ABX and OP flucloxacillin 12 g/day for 22 days	None
13	64	M	Native mitral valve endocarditis	IP ABX and OP benzylpenicillin 7.2 g/day for 19 days	None
14	84	M	Late prosthetic tissue aortic valve endocarditis	IP ABX and had OP ceftriaxone 2 g OD for 30 days	None
15	86	M	Suspected late prosthetic tissue aortic valve endocarditis	IP ABX and OP ceftriaxone 2 g OD for 28 days before admission with shortness of breath	None

Key: ABX = antibiotics; BD = twice daily; CK = creatine kinase; CRP = C-reactive protein; F = female; IP = inpatient; M = male; OD = once daily; OP = outpatient